Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Intangibles (2022 - 2026)

Axsome Therapeutics' Intangibles history spans 5 years, with the latest figure at $38.9 million for Q1 2026.

  • On a quarterly basis, Intangibles fell 38.95% to $38.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $38.9 million, a 38.95% decrease, with the full-year FY2025 number at $63.8 million, up 36.05% from a year prior.
  • Intangibles hit $38.9 million in Q1 2026 for Axsome Therapeutics, down from $63.8 million in the prior quarter.
  • Over the last five years, Intangibles for AXSM hit a ceiling of $63.8 million in Q2 2022 and a floor of $38.9 million in Q1 2026.
  • Historically, Intangibles has averaged $57.9 million across 5 years, with a median of $61.7 million in 2022.
  • Biggest five-year swings in Intangibles: soared 36.05% in 2025 and later tumbled 38.95% in 2026.
  • Tracing AXSM's Intangibles over 5 years: stood at $59.7 million in 2022, then fell by 10.69% to $53.3 million in 2023, then fell by 12.0% to $46.9 million in 2024, then skyrocketed by 36.05% to $63.8 million in 2025, then tumbled by 38.95% to $38.9 million in 2026.
  • Business Quant data shows Intangibles for AXSM at $38.9 million in Q1 2026, $63.8 million in Q4 2025, and $63.8 million in Q3 2025.